SG11201704942QA - Dengue virus vaccine compositions and methods of use thereof - Google Patents
Dengue virus vaccine compositions and methods of use thereofInfo
- Publication number
- SG11201704942QA SG11201704942QA SG11201704942QA SG11201704942QA SG11201704942QA SG 11201704942Q A SG11201704942Q A SG 11201704942QA SG 11201704942Q A SG11201704942Q A SG 11201704942QA SG 11201704942Q A SG11201704942Q A SG 11201704942QA SG 11201704942Q A SG11201704942Q A SG 11201704942QA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- dengue virus
- vaccine compositions
- virus vaccine
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24171—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462095331P | 2014-12-22 | 2014-12-22 | |
| PCT/US2015/066549 WO2016106107A2 (en) | 2014-12-22 | 2015-12-18 | Dengue virus vaccine compositions and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201704942QA true SG11201704942QA (en) | 2017-07-28 |
Family
ID=56151628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201704942QA SG11201704942QA (en) | 2014-12-22 | 2015-12-18 | Dengue virus vaccine compositions and methods of use thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10449243B2 (es) |
| EP (1) | EP3236997B1 (es) |
| JP (1) | JP2018502080A (es) |
| CN (1) | CN106999568A (es) |
| AU (1) | AU2015369875A1 (es) |
| BR (1) | BR112017013270A2 (es) |
| CL (1) | CL2017001595A1 (es) |
| CO (1) | CO2017005830A2 (es) |
| CR (1) | CR20170280A (es) |
| ES (1) | ES2981476T3 (es) |
| MX (1) | MX2017008342A (es) |
| MY (1) | MY192543A (es) |
| NI (1) | NI201700080A (es) |
| PH (1) | PH12017501165A1 (es) |
| SG (1) | SG11201704942QA (es) |
| WO (1) | WO2016106107A2 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170143817A1 (en) * | 2015-11-20 | 2017-05-25 | Oregon Health & Science University | Dengue virus vaccine |
| TWI625393B (zh) * | 2016-11-15 | 2018-06-01 | 國立清華大學 | 對抗複數種登革熱病毒血清型之疫苗套組及其製備方法與用途 |
| JOP20200140A1 (ar) | 2017-12-07 | 2022-10-30 | Merck Sharp & Dohme | صيغ لتركيبات لقاح فيروس حُمى الضنك |
| AU2020277403A1 (en) * | 2019-05-20 | 2022-01-06 | Soligenix, Inc. | Compositions and methods of manufacturing trivalent filovirus vaccines |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6184024B1 (en) | 1988-07-14 | 2001-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and/or growth-restricted flaviviruses |
| US6254873B1 (en) | 1995-04-17 | 2001-07-03 | The United States Of America As Represented By The Secretary Of The Army | Inactivated dengue virus vaccine |
| US6190859B1 (en) | 1995-04-17 | 2001-02-20 | The United States Of America As Represented By The Secretary Of The Army | Method and kit for detection of dengue virus |
| AU6093296A (en) | 1995-06-07 | 1996-12-30 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Infectious dengue 2 virus pdk-53 as quadravalent vaccine |
| EP0836090A1 (en) | 1996-10-12 | 1998-04-15 | Evotec BioSystems GmbH | Method of analysis of samples by determination of the distribution of specific brightnesses of particles |
| ES2244050T3 (es) | 1997-02-28 | 2005-12-01 | Acambis Inc. | Vacunas quimericas de flavivirus. |
| AU752191B2 (en) | 1997-07-31 | 2002-09-12 | Hawaii Biotech, Inc. | Recombinant dimeric envelope vaccine against flaviviral infection |
| CA2341354C (en) | 1998-09-02 | 2009-10-20 | The Government Of The United States Of America | Dengue viruses that are replication defective in mosquitos for use as vaccines |
| JP2002540170A (ja) | 1999-03-26 | 2002-11-26 | ウォルター リード アーミー インスティテュート オブ リサーチ | 弱毒化デング熱２型ウイルスワクチン |
| DE60041250D1 (de) | 1999-03-26 | 2009-02-12 | Us Army | Multivalenter dengue-virus impfstoff |
| US6537557B1 (en) | 1999-03-26 | 2003-03-25 | The United States Of America As Represented By The Secretary Of The Army | Attenuated dengue-4 virus vaccine |
| AU4179200A (en) | 1999-03-26 | 2000-10-16 | Walter Reed Army Institute Of Research | Attenuated dengue-1 virus vaccine |
| US6432411B1 (en) | 1999-07-13 | 2002-08-13 | Hawaii Biotechnology Group | Recombinant envelope vaccine against flavivirus infection |
| DK2290108T3 (da) | 2001-05-22 | 2014-10-20 | Us Gov Health & Human Serv | Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira, samt kimære dengue-vira |
| EP1471873A4 (en) | 2002-01-15 | 2005-03-16 | Acambis Inc | VACCINES AGAINST FLAVIVIRUS |
| ES2677348T3 (es) | 2002-05-03 | 2018-08-01 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Un virus del dengue quimérico recombinante rDEN3/4delta 30(ME), rDEN2/4delta30(ME) o rDEN1/4delta30(ME) que contiene una deleción de 30 nucleótidos (delta30) en una sección de la región no traducida en 3' del genoma del dengue de tipo 4, en donde dicha deleción de 30 nucleótidos se corresponde con la estructura tallo-bucle de TL2 |
| WO2003101397A2 (en) | 2002-05-31 | 2003-12-11 | Acambis, Inc. | Tetravalent dengue vaccines |
| US7189403B2 (en) | 2003-06-30 | 2007-03-13 | Institut Pasteur | Attenuated flavivirus strains containing a mutated M-ectodomain and their applications |
| AU2004304770B2 (en) | 2003-12-08 | 2010-05-06 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties by small oligonucleotide-based compounds |
| WO2006044857A2 (en) | 2004-10-20 | 2006-04-27 | Acambis Inc. | Vaccines against japanese encephalitis virus and west nile virus |
| CA2611934C (en) | 2005-06-17 | 2015-11-03 | Sanofi Pasteur | Dengue serotype 1 attenuated strain |
| JP5075120B2 (ja) | 2005-06-17 | 2012-11-14 | サノフィ・パスツール | デング熱セロタイプ２の弱毒化株 |
| MX2007016083A (es) | 2005-06-24 | 2008-03-10 | Intervet Int Bv | Vacunas quimericas inactivadas y metodos relacionados de uso. |
| WO2007015783A2 (en) | 2005-07-22 | 2007-02-08 | Research Development Foundation | Attenuated strains of flaviviruses , and uses thereof |
| US7470674B2 (en) | 2005-11-07 | 2008-12-30 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
| AR061197A1 (es) | 2006-06-07 | 2008-08-13 | Sanofi Pasteur | Cepas del virus 3 del dengue vivas atenuadas |
| USRE46042E1 (en) | 2006-08-15 | 2016-06-28 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Development of dengue virus vaccine components |
| FR2906724B1 (fr) | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
| ES2637629T3 (es) | 2006-11-09 | 2017-10-13 | The United States Of America As Represented By The Secretary Of The Navy | Inducción de una respuesta inmunitaria frente al virus del dengue usando un enfoque de sensibilización-refuerzo |
| US8440202B2 (en) | 2006-11-09 | 2013-05-14 | The United States Of America As Represented By The Secretary Of The Navy | Induction of an immune response against dengue virus using the prime-boost approach |
| BRPI0904020B8 (pt) | 2009-10-01 | 2021-05-25 | Fundacao Oswaldo Cruz | composição vacinal contra o vírus da dengue, e, kit |
| SG10201508700XA (en) | 2010-10-29 | 2015-11-27 | Merck Sharp & Dohme | Recombinant subunit dengue virus vaccine |
| WO2012065105A2 (en) * | 2010-11-12 | 2012-05-18 | Thomas Monath | Chimeric flavivirus vaccines |
| JP2015524422A (ja) * | 2012-07-24 | 2015-08-24 | サノフィ・パスツールＳａｎｏｆｉｐａｓｔｅｕｒ | ワクチン組成物 |
| CN105246506A (zh) | 2013-06-21 | 2016-01-13 | 默沙东公司 | 登革病毒疫苗组合物及其使用方法 |
-
2015
- 2015-12-18 CN CN201580070223.8A patent/CN106999568A/zh active Pending
- 2015-12-18 BR BR112017013270A patent/BR112017013270A2/pt not_active Application Discontinuation
- 2015-12-18 MX MX2017008342A patent/MX2017008342A/es unknown
- 2015-12-18 WO PCT/US2015/066549 patent/WO2016106107A2/en active Application Filing
- 2015-12-18 AU AU2015369875A patent/AU2015369875A1/en not_active Abandoned
- 2015-12-18 SG SG11201704942QA patent/SG11201704942QA/en unknown
- 2015-12-18 EP EP15874179.3A patent/EP3236997B1/en active Active
- 2015-12-18 MY MYPI2017000917A patent/MY192543A/en unknown
- 2015-12-18 JP JP2017533387A patent/JP2018502080A/ja active Pending
- 2015-12-18 CR CR20170280A patent/CR20170280A/es unknown
- 2015-12-18 US US15/536,319 patent/US10449243B2/en active Active
- 2015-12-18 ES ES15874179T patent/ES2981476T3/es active Active
-
2017
- 2017-06-14 CO CONC2017/0005830A patent/CO2017005830A2/es unknown
- 2017-06-16 CL CL2017001595A patent/CL2017001595A1/es unknown
- 2017-06-20 NI NI201700080A patent/NI201700080A/es unknown
- 2017-06-20 PH PH12017501165A patent/PH12017501165A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3236997A2 (en) | 2017-11-01 |
| WO2016106107A2 (en) | 2016-06-30 |
| EP3236997A4 (en) | 2018-05-30 |
| PH12017501165A1 (en) | 2017-12-11 |
| US20170360917A1 (en) | 2017-12-21 |
| CO2017005830A2 (es) | 2017-08-31 |
| AU2015369875A1 (en) | 2017-06-15 |
| CR20170280A (es) | 2017-08-21 |
| BR112017013270A2 (pt) | 2018-03-06 |
| JP2018502080A (ja) | 2018-01-25 |
| CL2017001595A1 (es) | 2018-01-26 |
| WO2016106107A3 (en) | 2016-08-18 |
| MY192543A (en) | 2022-08-26 |
| US10449243B2 (en) | 2019-10-22 |
| CN106999568A (zh) | 2017-08-01 |
| ES2981476T3 (es) | 2024-10-09 |
| NI201700080A (es) | 2017-07-18 |
| EP3236997B1 (en) | 2024-05-29 |
| MX2017008342A (es) | 2017-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263287A (en) | Neoepitope vaccines and methods of using them | |
| HK1247238B (zh) | 改造的crispr-cas9組合物和使用方法 | |
| HK1247636A1 (zh) | Rna指導的人類jc病毒和其他多瘤病毒的根除 | |
| ZA201700165B (en) | Influenza virus vaccines and uses thereof | |
| IL251834A0 (en) | Pharmaceutical compositions containing peptide variants and methods of using them | |
| SG11201703569XA (en) | HEPATITIS D VIRUS (HDV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | |
| HUE056172T2 (hu) | Szelenoorganikus vegyületeket tartalmazó készítmények és eljárások alkalmazásukra | |
| HK1248531A1 (zh) | 免疫調節組合物及其使用方法 | |
| ZA201701909B (en) | Trichoderma compositions and methods of use | |
| SG11201610443WA (en) | Influenza virus vaccines and uses thereof | |
| IL259894A (en) | Improved compositions and improved methods for viral delivery of neoepitopes and their use | |
| IL248160A0 (en) | Compositions of tissue fillers and methods of use | |
| SG11201702116VA (en) | Viral rna segments as immunomodulatory agents and vaccine components | |
| HK1254960A1 (zh) | 冷沉澱物組合物及其製備方法 | |
| SG11201701256RA (en) | Vaccine compositions against dengue virus diseases | |
| SG11201703366RA (en) | Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development | |
| SG11201510266SA (en) | Dengue virus vaccine compositions and methods of use thereof | |
| HK1255379A1 (zh) | 丙型肝炎病毒免疫原性組合物及其使用方法 | |
| SG11201510617WA (en) | Methods and compositions for dengue virus vaccines | |
| EP3169699A4 (en) | Cancer vaccine compositions and methods of use thereof | |
| SG11201704942QA (en) | Dengue virus vaccine compositions and methods of use thereof | |
| HK1243404A1 (zh) | 色酰胺組合物和使用方法 | |
| HK1248527A1 (zh) | 牙科組合物和使用方法 | |
| EP3157950A4 (en) | Influenza vaccines and methods of use thereof | |
| GB2537518B (en) | Settable compositions and methods of use |